SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-005614
Filing Date
2024-01-10
Accepted
2024-01-10 07:00:29
Documents
14
Period of Report
2024-01-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d129973d8k.htm   iXBRL 8-K 31368
2 EX-99.1 d129973dex991.htm EX-99.1 27386
6 GRAPHIC g129973g0110045634462.jpg GRAPHIC 5859
  Complete submission text file 0001193125-24-005614.txt   194817

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20240109.xsd EX-101.SCH 2869
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20240109_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20240109_pre.xml EX-101.PRE 10825
8 EXTRACTED XBRL INSTANCE DOCUMENT d129973d8k_htm.xml XML 3234
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 24524846
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)